SFI Advisors LLC bought a new stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 4,149 shares of the financial services provider’s stock, valued at approximately $564,000.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Glass Jacobson Investment Advisors llc lifted its position in shares of iShares Biotechnology ETF by 150.6% during the 3rd quarter. Glass Jacobson Investment Advisors llc now owns 203 shares of the financial services provider’s stock valued at $25,000 after acquiring an additional 122 shares during the period. PCA Investment Advisory Services Inc. purchased a new stake in iShares Biotechnology ETF in the 2nd quarter valued at approximately $28,000. Values First Advisors Inc. purchased a new stake in iShares Biotechnology ETF in the 4th quarter valued at approximately $43,000. Horizon Bancorp Inc. IN acquired a new stake in iShares Biotechnology ETF during the 3rd quarter valued at $44,000. Finally, Tennessee Valley Asset Management Partners purchased a new stake in shares of iShares Biotechnology ETF in the fourth quarter valued at $44,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.
iShares Biotechnology ETF Price Performance
Shares of IBB stock traded down $0.18 during mid-day trading on Tuesday, hitting $127.66. 573,471 shares of the company’s stock were exchanged, compared to its average volume of 1,790,993. The stock has a 50-day simple moving average of $135.82 and a two-hundred day simple moving average of $129.54. iShares Biotechnology ETF has a fifty-two week low of $111.83 and a fifty-two week high of $141.16.
iShares Biotechnology ETF Announces Dividend
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Recommended Stories
- Five stocks we like better than iShares Biotechnology ETF
- What Is WallStreetBets and What Stocks Are They Targeting?
- Silicon Motion Proves That AI in Motion Stays in Motion
- What Does Downgrade Mean in Investing?
- Undervalued UnitedHealth Group Won’t Be For Long
- Investing In Preferred Stock vs. Common Stock
- The 5 Stocks Most Sold By Insiders This Year
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.